PB6440

AssetAlso called SE-6440, VT-6440

Selectively inhibits aldosterone synthase to reduce aldosterone production and lower blood pressure.

Stage
Preclinical, no development reported
Modality
Small molecule
Target
CYP11B2
1
Indication
0
Trials
1
Developer

No development reported since January 2020. Last activity: Development reported. SEC filing

Indications

1
  • Treatment-resistant hypertension

    Preclinical, SEC filing, Jan 13, 2020

In the full profile

  • Target and mechanism1
  • Owner and partners3
  • Evidence for its targets1
  • Competitors4

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets